targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringdate 1965-04-01 00:00:00
2050-12-01 00:00:00
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000037280
|
MONDO_0021640
|
NCT00923117
|
Terminated
| 2
|
2008-06-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 180,388,627,053
|
The study was terminated based on results of an interim analysis for futility.
|
Phase 2
|
30/06/2008
|
Terminated
|
30/09/2015
|
30/06/2012
|
Negative
|
Negative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
cancer_gene_census
|
somatic_mutation
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT00923117
|
Terminated
| 2
|
2008-06-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 180,388,627,053
|
The study was terminated based on results of an interim analysis for futility.
|
Phase 2
|
30/06/2008
|
Terminated
|
30/09/2015
|
30/06/2012
|
Negative
|
Negative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT00923117
|
Terminated
| 2
|
2008-06-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 180,388,627,053
|
The study was terminated based on results of an interim analysis for futility.
|
Phase 2
|
30/06/2008
|
Terminated
|
30/09/2015
|
30/06/2012
|
Negative
|
Negative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
cancer_gene_census
|
somatic_mutation
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT00923117
|
Terminated
| 2
|
2008-06-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 180,388,627,053
|
The study was terminated based on results of an interim analysis for futility.
|
Phase 2
|
30/06/2008
|
Terminated
|
30/09/2015
|
30/06/2012
|
Negative
|
Negative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT03275558
|
Withdrawn
| 1
|
2018-07-17
|
Withdrawn
|
stopped
| null | null | null | 1,382,979,470,027
|
Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)
|
Phase 1
|
17/07/2018
|
Withdrawn
|
19/07/2018
|
17/07/2018
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
cancer_gene_census
|
somatic_mutation
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT03275558
|
Withdrawn
| 1
|
2018-07-17
|
Withdrawn
|
stopped
| null | null | null | 1,382,979,470,027
|
Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)
|
Phase 1
|
17/07/2018
|
Withdrawn
|
19/07/2018
|
17/07/2018
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT03275558
|
Withdrawn
| 1
|
2018-07-17
|
Withdrawn
|
stopped
| null | null | null | 1,382,979,470,027
|
Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)
|
Phase 1
|
17/07/2018
|
Withdrawn
|
19/07/2018
|
17/07/2018
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
cancer_gene_census
|
somatic_mutation
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT03275558
|
Withdrawn
| 1
|
2018-07-17
|
Withdrawn
|
stopped
| null | null | null | 1,382,979,470,027
|
Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)
|
Phase 1
|
17/07/2018
|
Withdrawn
|
19/07/2018
|
17/07/2018
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT03275558
|
Withdrawn
| 1
|
2018-07-17
|
Withdrawn
|
stopped
| null | null | null | 1,382,979,470,027
|
Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)
|
Phase 1
|
17/07/2018
|
Withdrawn
|
19/07/2018
|
17/07/2018
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
cancer_gene_census
|
somatic_mutation
| 413,311
|
ENSG00000037280
|
MONDO_0021640
|
NCT03275558
|
Withdrawn
| 1
|
2018-07-17
|
Withdrawn
|
stopped
| null | null | null | 1,382,979,470,027
|
Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)
|
Phase 1
|
17/07/2018
|
Withdrawn
|
19/07/2018
|
17/07/2018
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03772561
|
Recruiting
| 1
|
2018-12-03
| null | null | null | null | null | 309,237,645,462
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894243
|
Completed
| 1
|
2014-03-13
| null | null | null | null | null | 326,417,514,702
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01894256
|
Completed
| 1
|
2013-11-01
| null | null | null | null | null | 403,726,927,788
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03318445
|
Completed
| 1
|
2018-01-12
| null | null | null | null | null | 609,885,356,962
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03101280
|
Completed
| 1
|
2017-04-27
| null | null | null | null | null | 678,604,834,304
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
| null | null | 3
| null | null | null | null |
Phase III+
|
Phase II+
| 755,914,244,853
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01851265
|
Completed
| 1
|
2013-07-04
| null | null | null | null | null | 841,813,590,741
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01419548
|
Withdrawn
| 1
|
2011-07-29
|
Withdrawn
|
stopped
| null | null | null | 841,813,590,937
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT03878095
|
Recruiting
| 2
|
2019-12-02
| null | null | null | null |
Phase II+
| 1,022,202,217,130
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4
|
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000041880
|
EFO_0000616
|
NCT01929603
|
Completed
| 1
|
2013-12-01
| null | null | null | null | null | 1,022,202,217,519
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.